Advertisement
Advertisement
ALNY
Alnylam Pharmaceuticals, Inc.
237.10
USDSponsored
+0.54
+0.23%
Aug 28, 15:59 UTC -4
Closed
After-Market
242.06
+4.96
+2.09%
ALNY Earnings Reports
Positive Surprise Ratio
ALNY beat 22 of 42 last estimates.
52%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.47B
/$1.67
Implied change from Q2 26 (Revenue/ EPS)
+13.47%
/+38.02%
Implied change from Q3 25 (Revenue/ EPS)
+17.55%
/-20.85%
Alnylam Pharmaceuticals, Inc. earnings per share and revenue
On Jul 30, 2026, ALNY reported earnings of 1.21 USD per share (EPS) for Q2 26, missing the estimate of 1.58 USD, resulting in a -23.70% surprise. Revenue reached 1.29 billion, compared to an expected 1.35 billion, with a -4.14% difference. The market reacted with a -28.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 16 analysts forecast an EPS of 1.67 USD, with revenue projected to reach 1.47 billion USD, implying an increase of 38.02% EPS, and increase of 13.47% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Immatics N.V. Ordinary Shares
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.46
Surprise
-5.70%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-Surprise
-
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-Actual
-$0.35
Surprise
-
LeonaBio, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$1.28
Actual
-$0.80
Surprise
+37.97%
Chemomab Therapeutics Ltd. - ADR
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.24
Surprise
-56.86%
Adial Pharmaceuticals, Inc
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$1.05
Actual
-$11.25
Surprise
-968.17%
Senti Biosciences Holdings, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.41
Surprise
-51.68%
FAQ
What were Alnylam Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Alnylam Pharmaceuticals, Inc. reported EPS of $1.21, missing estimates by -23.7%, and revenue of $1.29B, -4.14% below expectations.
How did the market react to Alnylam Pharmaceuticals, Inc.'s Q2 2026 earnings?
The stock price moved down -28.31%, changed from $286.62 before the earnings release to $205.48 the day after.
When is Alnylam Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Alnylam Pharmaceuticals, Inc.'s next earnings report?
Based on 16
analysts, Alnylam Pharmaceuticals, Inc. is expected to report EPS of $1.67 and revenue of $1.47B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement